|
Audioconference Agenda
|
|
National Pharma Audioconference: Lessons from Merck's $671 Million Medicaid Drug Pricing Settlement
- Wednesday, March 26, 2008
1:00 pm - 3:00 pm (Eastern)
12:00 pm - 2:00 pm (Central)
11:00 am - 1:00 pm (Mountain)
10:00 am - 12:00 pm (Pacific)
|
|
|
The Audioconference agenda is set forth in Eastern Daylight Time below:
Audioconference Background Materials (provided by Mark Kleiman):
|
|
1:00 pm |
Introduction and Overview of Case
Robert G. Homchick, Esq. (Moderator)
|
1:05 pm |
Incentives to M.D.s - Type & Extent
Viveca D. Parker, Esq., Tim Terry, Esq. and BethAnne Yeager, Esq.
|
1:10 pm |
Incentive - Proof Issues & Damage Models
Steven H. Cohen, Esq., Paul E. Kalb, JD, MD, Patrick J. Keenan, Esq. and Viveca D. Parker, Esq.
|
1:20 pm |
Nominal Price Violations: Hx of Nominal Price Exception, Nature of Nominal Price Violations Alleged and Merck's Defenses
Paul E. Kalb, JD, MD, Mark Allen Kleiman, Esq., Viveca D. Parker, Esq. and Tim Terry, Esq.
|
1:35 pm |
Nevada Litigation
Tim Terry, Esq. and BethAnne Yeager, Esq.
|
1:45 pm |
Sharpening the Case - The New Model: The Joint Investigative Process, Limits on Federal Resources, Nevada's Initiative and Federal / NAMFCU Support for Nevada Litigation
Steven H. Cohen, Esq., Patrick J. Keenan, Esq., Viveca D. Parker, Esq. and Tim Terry, Esq.
|
2:05 pm |
Federal - State - Relator Cooperation:
- EDPA Presentation to NAMFCU Qui Tam Comm
Mark Allen Kleiman, Esq. and Viveca D. Parker, Esq.
- NAMFCU Decision-Making Process
Patrick J. Keenan, Esq. and Tim Terry, Esq.
- State - Federal Investigation
Steven H. Cohen, Esq., Patrick J. Keenan, Esq., Viveca D. Parker, Esq. and Tim Terry, Esq.
|
|
2:20 pm |
The Settlement Process
Steven H. Cohen, Esq., Paul E. Kalb, JD, MD, Patrick J. Keenan, Esq., Viveca D. Parker, Esq. and Tim Terry, Esq.
|
2:35 pm |
Lessons Learned
Paul E. Kalb, JD, MD, Mark Allen Kleiman, Esq., Viveca D. Parker, Esq. and Tim Terry, Esq.
|
2:45 pm |
Comments, Questions and Answers
Robert G. Homchick, Esq. (Moderator)
|
3:00 pm |
Audioconference Adjournment
|
|
|
|
|
